Mithrl Raises $20M Series A

Mithrl, a company based in the United States that develops an artificial intelligence platform for biopharmaceutical research, has raised $20 million in Series A funding. The company aims to accelerate the transition from initial research ideas to Investigational New Drug (IND) applications.

Investors

The funding round was led by Obvious Ventures. Additional participants included Headline, AGI House, and several pharmaceutical executives.

Mithrl Use of Funds

The company plans to use the new capital to support the development of the second generation of its biomedical world model platform. Additionally, the funds will support increasing the company's headcount to meet rising demand for platform deployments and to expand the technology's application across therapeutic areas such as oncology, diabetes, metabolic disease, and cardiovascular disease.

About Mithrl

Founded in 2023 by Vivek Adarsh, Mithrl is an AI company that provides a platform combining curated, peer-reviewed biomedical research with proprietary data to help biopharmaceutical companies generate scientific hypotheses and conduct research. Its platform is powered by a proprietary biomedical world model built on peer-reviewed scientific evidence, partnered datasets, and customers’ proprietary data.

Funding Details

Company Website: https://mithrl.com

Company: Mithrl
Raised: $20M
Round: Series A
Funding Date: September 15, 2026
Lead Investor: Obvious Ventures
Additional Investors: Headline, AGI House, and several pharma executives
Software Category: Artificial Intelligence for Biopharma
Source: https://www.genengnews.com/topics/artificial-intelligence/mithrl-raises-20m-to-expand-deployment-of-its-biomedical-world-model-across-biopharma/